This post Ray's Little Known Secret to BIG Biotech Profits appeared first on Daily Reckoning.

Dear Tech Profits Reader,

Those who have followed Ray over the years know he spends countless hours poring over tons of company info and data every day.

But until now, we've never shown you how he knows where to start his search.

Today, we're pulling back the curtain to show you how Ray uses the treasure trove of info housed in plain site by the FDA to pick the very best in biotech stocks before they soar in value.

Read on below?

FDA Approvals Mean Red-Hot Biotech Gains for 2018

Today I want to pull back the curtain and explain how I use a little known Federal Drug Administration secret to identify the best biotech stocks that could trigger big profits in months.

One that tells me exactly when drug companies expect to receive approval from the FDA.

This information is an incredibly valuable first step when I begin researching a biotech stock.

Because if a company's drug gets a thumbs up from the FDA, they're free to start marketing its drug.

And share prices could soar.

Now you should know that there's literally pages upon pages of this data to monitor.

It's not as simple as throwing a dart at the FDA calendar and landing on a winner.

But this information allows me to target my research to find the very best stocks that the biotech sector has to offer.

In short, I start with the FDA's PDUFA dates.

PDUFA stands for the Prescription Drug User Fee Act, most recently reauthorized by Congress in 2012. It's a promise the government makes to companies to approve or reject new drugs much faster than in the past.

And it forces the FDA to get new lifesaving drugs to the market faster and in a more predictable fashion.

The biotech company pays the FDA a fee to review their drug. And in turn, the FDA gives the company an exact date when they plan to approve or deny the drug.

For us investors, these PDUFA dates create an absolute trader's paradise.

Here are two examples from last year.

Amgen (NASDAQ: AMGN) for example, announced FDA approval of its heart-attack prevention therapy on Dec 1. Immediately after, the stock popped 15% in less than two months, moving from $177.20 to $199.

Another prime example is Puma Biotechnology Inc. (NASDAQ: PBYI). On July 17 last year, the company announced it received FDA approval for its new breast cancer treatment.

In the two weeks that followed, the stock steadily rose from $86.10 to $97.60.

An increase of 13% in two weeks.

And if you held on through the brief sell-off that followed you could have cashed out in December at $132.45 per share.

That's a gain of almost 54% in 5 months!

All off one good trial result.

The point is, following FDA trials can instantly put you into position for potentially enormous market returns.

In fact, one of my favorite biotech's for 2018 is currently on deck for FDA approval.

The date is set for April 27, and with a positive result this tiny biotech could soar.

It's your best chance to get in on the ground-floor of what could be the single hottest biotech play of the year.

For Technology Profits Daily,

Ray Blanco
Chief Technology Expert, Technology Profits Daily

Editor's note: Ray's identified a biotech stock that, according to a secret document, could score you up to 1,500% in profits.

Believers and non-believers alike will be shocked when they see this. But this opportunity will strike on April 27. Get your insider access today by clicking here.

The post Ray's Little Known Secret to BIG Biotech Profits appeared first on Daily Reckoning.